$120.80
-22.86 (-15.91%)
GRAL News3 articles
GRAIL Soars 35% Ahead of FDA Panel, Topping All Analyst Price Targets
GRAIL shares surge 34.7% to $108.78 two days before FDA panel review of Galleri test, outpacing all analyst price targets as investors price in approval.
BillionToOne Slumps 39% as Guidance Signals Slower H2 Growth
BillionToOne (NASDAQ:BLLN) shares fell 39% after maintaining full-year guidance, suggesting a sharp slowdown in H2 growth. Q2 revenue jumped 64% to $109.4M, but investors focused on the deceleration.
Grail Shares Halve as UK Trial Misses Primary Endpoint, Clouding FDA Path
GRAIL Inc. shares plummeted almost 50% in Friday trading following disappointing results from a major UK study of its multi-cancer early detection test. The trial's failure to hit its primary endpoint complicates the company's regulatory and reimbursement strategy.